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Introduction: Recently, a great interest has arisen for salivary gland ultrasonography (SGUS) as a valuable tool for
the assessment of major salivary gland involvement in primary Sjögren’s syndrome (pSS. The aims of this study
were to test the accuracy of SGUS for the early detection of pSSand to compare the diagnostic performance of
SGUS with minor salivary gland biopsy (MSGB) and unstimulated salivary flow (USFR) in this context.
Method: Patients with suspected pSS and symptoms duration of ≤5 years were consecutively enrolled in this study. The
diagnosis of pSS was made according to the AECG criteria. SGUS was performed by two radiologists blinded to
the diagnosis and a previously reported ultrasound scoring system (De Vita et al. 1992, cut-off ≥ 1) was used to
grade the echostructure alterations of the salivary glands. Statistical analysis was performed using SPSS v16.
Results: This study included 50 pSS patients and 57 controls with no-SS sicca symptoms. The mean(SD) age of
the pSS group was lower than non-SS group (47(13) vs 53(12)yrs, p = 0.006). No further differences between
the two groups were observed. Patients with pSS showed a significantly higher SGUS score in comparison with
controls (mean(SD) = 2.1(1.8) vs 0.0(0.4), p = 0.000). The SGUS cut-off ≥ 1 showed a sensitivity (SE) of 66 %, a
specificity (SP) of 98 %, a positive predictive value (PPV) of 97 % and a negative predictive value (NPV) of 73 %
for pSS diagnosis. The SGUS score correlated also with patients’ MSGB/FS and USFR.
Conclusions: This study confirmed the good performance of SGUS for the early non-invasive diagnosis of pSS. Further
research in larger international cohort of patients is mandatory in order to assess the role of SGUS in the
diagnostic algorithm of pSS.Introduction
Chronic inflammation and progressive dysfunction of saliv-
ary and lachrymal glands are among the most distinctive
features of primary Sjögren’s syndrome (pSS). Currently,
the involvement of salivary glands in pSS is assessed by
means of complementary tests such as sialometry, sialoscin-
tigraphy and sialography, in accordance with the American
European Consensus Group (AECG) classification criteria.
Such tests, added to biopsy of the minor salivary gland
(MSGB), may provide valuable information on the anatom-
ical and functional damage in these glands [1]; however,
their use in clinical practice is limited by poor specificity for* Correspondence: chiara.baldini74@gmail.com
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creativecommons.org/publicdomain/zero/1.0/pSS diagnosis. On the other hand, sialography and MSGB
are undoubtedly more specific tools but they are quite inva-
sive and may cause distress to the patients [2–4]. Routine
histopathological minor salivary gland assessment has im-
portant prognostic value [5–7]. However, doubt has re-
cently arisen as to the reliability of MSGB following reports
of discrepancies noted across different rheumatology cen-
ters [8, 9]. Therefore there is a growing interest in searching
for alternative, non-invasive and reliable diagnostic tools
potentially able to improve the diagnostic algorithm for pSS
[10]. In this context, a number of publications have de-
scribed convincing findings on the role of salivary gland
ultrasonography (SGUS) as an easy, non-invasive, widely
available imaging technique for the assessment of salivary
gland involvement in pSS [11–14]. In the clinical setting
SGUS has good diagnostic properties [15–19]. Yet the valuerticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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very early stages of the disease is still being assessed. More
specifically, it is still a matter of debate whether at the onset
of the disease, SGUS could eventually replace MSGB in
routine clinical practice.
The primary aim of this study therefore, was to test
the accuracy of SGUS for the early detection of pSS, par-
ticularly in distinguishing pSS from idiopathic sicca syn-
drome in patients manifesting sicca symptoms for less
than five years. The secondary aim of the study was to
compare the diagnostic performance of SGUS with
MSGB in the early detection of pSS in order to verify
whether SGUS might at least limit the indications for
MSGB in the clinical setting.
Methods
Study design and study population
This single-center, cross-sectional study included pa-
tients with suspected pSS, recent onset of dry eyes and
dry mouth, and manifestion of sicca symptoms for less
than 5 years, and who had presented between January
2011 and March 2013 to the University of Pisa tertiary-
care referral centre for pSS. The definitive diagnosis of
pSS was made in accordance with the AECG criteria [1].
Patients who did not fulfill the AECG criteria for pSS
and received a diagnosis of idiopathic sicca syndrome
represented the controls. More specifically, idiopathic
sicca syndrome was defined as a condition of persistent,
not immune-mediated dry eyes and dry mouth in pa-
tients without any systemic disorders potentially respon-
sible for dry eyes and dry mouth (i.e., viral or bacterial
infections, sarcoidosis, IgG4 disease, etc.). Patients with
secondary SS or subjects presenting with dry mouth and
dry eyes in the context of other rheumatic systemic dis-
eases were excluded from the study. All subjects gave in-
formed consent for all procedures, which were carried
out in accordance with the principles set in the Declar-
ation of Helsinki. The Institutional Review Board at the
University of Pisa, Italy, approved this study.
According to the AECG criteria, a complete work up
for pSS was performed in all the patients and controls,
including a standardized clinical examination performed
by the same rheumatologist, serological and laboratory
tests, ocular tests, assessment of the unstimulated saliv-
ary flow rate (USFR) and MSGB. The patient informa-
tion collected included: 1) gender; 2) age at inclusion in
the study; 3) history of dry eyes/mouth and/or recurrent
parotid enlargement assessed by the AECG question-
naire; 4) duration of subjective sicca symptoms; 5) symp-
toms/signs suggestive of disease-related extraglandular
manifestations, defined according to previous studies,
and 6) comorbidities and related treatments. Immuno-
logic tests included: antinuclear antibodies (ANA) deter-
mined by indirect immunofluorescence assay on HEp-2cells (a titer ≥1.160 was considered positive), rheumatoid
factor (RF) detected by nephelometry, and antibodies to
the extractable nuclear antigens Ro/SS-A and La/SS-B,
detected by ELISA. Schirmer’s test and the Lissamine
green test were performed and scored as described else-
where [1]. The USFR was assessed by sialometry. MSGB
was graded according to the focusing system [1]. The
SGUS examination was performed simultaneously to the
other diagnostic procedures being undertaken in all of
the 107 subjects.Ultrasonography examination
SGUS was performed in all patients by two expert radi-
ologists blinded to the patients’ clinical data. The inter-
observer reliability was estimated using the kappa index,
assessing each of the different US parameters separately.
Both the parotid and the submandibular glands were
scanned with the patients lying in the supine position
with the neck hyper-extended and the head slightly
turned to the opposite site. The parotid glands were
scanned in both the longitudinal and transverse planes,
and the submandibular glands were scanned only in the
longitudinal plane. The procedure was performed using
the Logiq 9 (General Electric Medical Systems, Milwaukee,
WI, USA) equipped with a multifrequency linear probe
operated at 10 MHz. The following ultrasound (US) pa-
rameters were analyzed and recorded in a predefined form
as follows: 1) assessment of gland size (i.e., normal, in-
creased, decreased), parenchymal echogenicity, parenchy-
mal inhomogeneity, and posterior glandular border
(visible/non-visible). Parenchymal echogeneity was defined
as normal or increased in comparison with the thyroid
gland parenchyma and the surrounding soft tissue (mus-
cular structures, subcutaneous fat etc.); 2) changes in the
echostructure of the glands were scored according to the
scoring system of de Vita et al. [20], which mostly focuses
on the inhomogeneity of gland tissue (i.e., the typical ab-
normal echostructure of the glands), with scores ranging
from 0 (i.e., homogenous glands) to 3 (grossly inhomogen-
eous gland). A mild level of inhomogeneity (score 1) was
attributed to isolated hypoechoic areas, while an evident
level of inhomogeneity (score 2) was assigned to evident
scattered hypoechoic areas with variable size, not uni-
formly distributed, and/or to multiple punctate or linear
non-shadowing densities, and 3) a gross level of inhomo-
geneity (score 3) was attributed to large round or conflu-
ent hypoechoic areas, and/or to linear densities, and/or to
multiple cysts or multiple calcifications. The global SGUS
score (0–6) was represented by the sum of the scores of
each pair of parotid and submandibular glands. If hom-
onymous glands were discordant for the degree of in-
homogeneity, the higher degree was considered in
assessing the (0–3) single score.
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Data were expressed as median (IQR) for continuous vari-
ables and as absolute frequencies and percentages for
nominal variables. Comparisons were made using the
parametric Student’s t test and non-parametric Mann-
Whitney U test, as applicable. Dichotomous variables were
compared using contingency table analysis and Fisher’s
exact test. Spearman’s rank correlation was used to assess
correlation between the SGUS score and different study
parameters, including USFR and MSGB focus scores.
In all statistical tests, a p value <0.05 was considered
statistically significant. The interobserver agreement
was assessed by using Cohen’s kappa coefficient. Simi-
larly the concordance between US score and different
pSS diagnostic tests and procedures was carried out
using Cohen’s kappa coefficient. A Cohen’s kappa
value >0.70 was considered satisfactory. Statistical
analysis was performed by SPSS version 16 (SPSS Inc.,
Chicago IL, USA).Results
Study cohort
The study cohort consisted of 107 subjects, of whom 50
had definitive pSS and 57 had idiopathic sicca syndrome.
Table 1 summarizes the characteristics of the patients.
The mean age of the pSS group was lower than the non-
pSS group (47 (13) vs 53 (12) yrs, p = 0.006). No further
differences between the two groups were observed with
respect to gender, frequency and duration of dry mouth
and dry eye symptoms and objective features of dry eyes.Table 1 Characteristics of the study population
Characteristics Primary Sjögren’s
syndrome
(n = 50)
No Sjögren’s
syndrome
(n = 57)
P value
Age, years, mean (SD) 47 (13) 53 (12) 0.006
Symptom duration,
mean (SD)
2.3 (1.8) 2.1(1.7) ns
Female sex, number (%) 48 (96 %) 55 (97 %) ns
Xerophtalmia, number (%) 44 (88 %) 47 (83 %) ns
Xerostomia, number (%) 46 (92 %) 49 (86 %) ns
Abnormal ocular tests,
number (%)
37 (74 %) 32 (56 %) ns
USFR, ml/15 minutes,
mean (SD)
2.3 (2.6) 4.8 (3.4) <0.0001
Focus score, mean (SD) 3.0 (2.3) 0(0) <0.0001
Hypergammaglobulinemia,
number (%)
27 (54 %) 3 (5 %) <0.0001
Rheumatoid factor,
number (%)
26 (52 %) 4 (7 %) <0.0001
Anti-Ro/SSA, number (%) 30 (60 %) 1 (2 %) <0.0001
Anti-La/SSB, number (%) 17 (34 %) none <0.0001
USFR unstimulated salivary flow rateUltrasonography results
Salivary gland size and parenchymal echostructure
Salivary gland size was measured for parotid and subman-
dibular glands in pSS patients and subjects with idiopathic
sicca syndrome. There was correlation between the gland
surface areas on the right and on the left sides and no sig-
nificant differences were detected in major salivary gland
surfaces between the two groups. The interobserver agree-
ment on hypoechogenicity was good, with a Cohen’s kappa
value of 0.80. Cohen’s kappa values for homogenicity were:
0.80, 0.70 and 0.90 for grades 1, 2 and 3, respectively.
Cohen’s kappa values for glandular size were 0.82 for par-
otid glands and 0.93 for submandibular glands. Finally,
Cohen’s kappa value for the posterior glandular border was
0.73. The echogenicity of the parotid glands was increased
in 22/50 pSS patients (44 %) vs 2/57 subjects without pSS
(3.5 %), whereas the echogenicity of the submandibular
glands was increased in 34/50 of the pSS patients (68 %) vs
4/57 subjects without pSS (7 %). Among the parameters an-
alyzed, inhomogeneity was the most significant in discrim-
inating pSS patients from subjects with idiopathic sicca
syndrome. More specifically, abnormal SGUS findings were
detected in about 66 % of pSS patients and in fewer than
10 % of controls (p <0.0001).
Table 2 summarizes the inhomogeneity scores for the
parotid and submandibular glands in patients with and
without pSS. Examples of the parenchymal inhomogeneity
grades of both parotid and submandibular glands in pa-
tients with pSS and in controls are shown in Figs. 1 and 2.
Concordance between the parotid and the submandibular
ultrasonographic grades was high with a Cohen’s kappa
value of 0.764. The overall SGUS score was significantly
higher in pSS patients compared to subjects with idiopathic
sicca syndrome (2.1 (1.8) vs 0.1 (0.4), p <0.0001). The SGUS
score correlated inversely with the USFR (r = −0.37,
p <0.0001) and directly with the MSGB focus scoreTable 2 Prevalence of SGUS scores in patients with and
without primary Sjögren’s syndrome
Primary Sjögren’s
syndrome (n = 50)
No Sjögren’s
syndrome (n = 57)
P value
SGUS (parotid
glands)
Score 0 17/50 (34 %) 52/57 (91.2 %) <0.0001
Score 1 15/50 (30 %) 5/57 (8.8 %) <0.0001
Score 2 15/50 (30 %) none <0.0001
Score 3 3/50 (6 %) none <0.0001
SGUS (submandibular
glands)
Score 0 23/50 (46 %) 56/57 (98.2 %) <0.0001
Score 2 24/50 (48 %) 1/57 (1.8 %) <0.0001
Score 3 3/50 (6 %) 0/57 <0.0001
SGUS salivary gland ultrasonography score
Fig. 1 Parenchymal inhomogeneity in the submandibular glands demonstrated by ultrasonography. a Normal submandibular gland (grade 0).
b Submandibular gland with evident inhomogeneity (grade 2). c, d Submandibular glands with gross inhomogeneity (grade 3)
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significantly higher in patients with a USFR <1.5 ml/15 mi-
nutes (2.6 ± 1.7 vs 0.9 ± 1.5, p <0.0001) and in patients with
an MSGB FS ≥1 (2.0 ± 1.8 vs 0.1 ± 0.7, p <0.0001).
Diagnostic value of salivary gland echostructure
Consistent with previous studies [13, 20] a cutoff of 2 for
the SGUS score allowed us to obtain the best ratio between
sensitivity and specificity. The cutoff of 2 was associated
with 66 % sensitivity, 98 % specificity, 97 % positive predict-
ive value (PPV) and 77 % negative predictive value (NPV).
Table 3 summarizes the diagnostic accuracy of the SGUS in
comparison to anti-Ro/SSA, Schirmer’s test and the MSGB
focus score. With a cutoff of 2 the diagnostic performance
of SGUS was very similar to that observed for the presence
of anti-Ro/SSA antibodies in terms of fairly good sensitivity
and high specificity: The SGUS score was less sensitive, but
more specific than Schirmer’s test. In comparison to
MSGB, the SGUS had similar specificity but lower sensitiv-
ity, with moderate agreement between the two procedures
(kappa Cohen’s value = 0.573). The PPV of the SGUS was
higher than for the MSGB alone, which means that whenthe SGUS results were positive, 33/34 pSS patients (97 %)
had been correctly classified. The probability of correctly
classifying patients as having pSS was even higher than with
the MSGB alone, as only 30/34 pSS patients (88 %) were
correctly classified on the basis of the MSGB alone. On the
other hand, the NPV of the SGUS score was lower; there-
fore the probability of correctly classifying the subjects as
not having pSS when the SGUS results were negative was
only 77 % (i.e., 56/73 subjects with idiopathic sicca syn-
drome were correctly classified). As a consequence 17/73
pSS patients would have been misclassified on the basis of
the SGUS alone without the MSGB. Figure 3 represents the
receiver operator characteristic (ROC) curves showing the
diagnostic accuracy of the SGUS score (range 0–6) assigned
to the parenchymal inhomogeneity (area under the
curve (AUC) = 0.82, 95 % CI 0.74, 0.91) and of the
MSGB (AUC = 0.96, 95 % CI 0.92, 1) for pSS.
Discussion
This study aimed to assess the diagnostic accuracy of
SGUS for the early detection of pSS. Indeed, our find-
ings confirmed the potential of SGUS to distinguish pSS
Fig. 2 Parenchymal inhomogeneity in the parotid glands demonstrated by ultrasonography. a Normal parotid gland (grade 0). b Parotid gland with mild
unspecific inhomogeneity (grade 1). c Parotid gland with evident inhomogeneity (grade 2). d Parotid gland with gross inhomogeneity (grade 3)
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and high specificity, even at the early stages of the dis-
ease. To date, only a limited number of studies have ex-
plored the diagnostic value of SGUS for the early
detection of pSS. In fact, Cornec et al. [11] investigated
the diagnostic accuracy of SGUS in 84 patients with pSS
with disease duration ≤5 years, and reported sensitivity
of 65.8 % and a specificity of 95.3 %, which is similar to
our findings. Other authors have also investigated the
performance of SGUS in patients with suspected pSS
upon diagnosis of the disease, but did they did not assess
the duration of the sicca symptoms prior to the diagno-
sis [15, 18, 19, 21–28].Table 3 Diagnostic accuracy of salivary gland ultrasonography (cuto
Schirmer’s test and minor salivary gland biopsy focus score
Sensitivity Specificity
SGUS ≥2 33/50 (66 %) 56/57 (98 %)
Anti-Ro/SSA antibodies 30/50 (60 %) 56/57 (98 %)
Schirmer’s test 37/50 (74 %) 32/57 (56 %)
MSGB 46/50 (92 %) 56/57 (98 %)
SGUS salivary gland ultrasonography score, MSGB minor salivary gland biopsyConversely, our study specifically limited enrollment
to patients at the onset of the disease. Hence, rather
than addressing the duration of the disease, we focused
on the duration of the symptoms reported by the pa-
tients and developed an ad hoc patient questionnaire.
This allowed us to specifically study only patients com-
plaining of sicca symptoms for <5 years in order to dem-
onstrate the accuracy of SGUS for diagnosis of pSS at
the early stages of disease in these patients. Intriguingly,
by using a scoring system mainly focused on salivary
gland inhomogeneity, we were able to demonstrate that
changes in the salivary gland parenchymal echostructure
appeared relatively early in the course of the disease,ff score of 2), in comparison with anti-Ro/SSA antibodies,
Positive predictive value Negative predictive value
33/34 (97 %) 56 /73 (77 %)
30/31 (97 %) 56/67 (74 %)
37/62 (60 %) 32/45 (71 %)
46/47 (98 %) 56/60 (93 %)
Fig. 3 Receiver operator characteristic curves show the diagnostic accuracy of the salivary gland ultrasonography (SGUS) score assigned to the
parenchymal inhomogeneity (area under the curve (AUC) = 0.82, 95 % CI 0.74, 0.91) and of the minor salivary gland biopsy (AUC = 0.96, 95 % CI
0.92, 1) for primary Sjögren’s syndrom
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dibular findings. In line with these data and despite the
different scoring systems adopted, all the available stud-
ies have highlighted parenchymal gland inhomogeneity
as the most important distinctive feature for differentiat-
ing pSS from other salivary gland disorders [17]. The
SGUS score for inhomogeneity was also the parameter
in which interobserver agreement between the radiolo-
gists was the highest, reinforcing the reliability and the
feasibility of SGUS in daily clinical practice. In addition,
the SGUS score was significantly correlated with both
the USFR and the MSGB focus score. Therefore, SGUS
appeared to mirror dysfunction of the salivary glands
and inflammation even in the early stage of the disease.
The agreement between SGUS and MSGB was not sur-
prising, because Vitali et al. [29] demonstrated a good
level of concordance between minor and major salivary
gland involvement in pSS. However, from a practical
point of view, our findings demonstrated that SGUS and
minor salivary gland histopathology were not inter-
changeable. More specifically, we speculated that when
the SGUS results were negative, MSGB should remain
mandatory in order to avoid patient misclassification. By
contrast, in patients who have declined biopsy but have
a positive SGUS score this may be helpful in routine
care. In our study, 33 out of 107 patients (31 %) with
pathological findings at the SGUS could have been cor-
rectly diagnosed as having pSS without assessment of
the MSGB, thus, additionally supporting the value of
SGUS for non-invasive diagnosis of the disease.Despite these encouraging results, our study did have
some limitations. First, we used a SGUS score that sim-
ply distinguished glands with normal parenchyma from
those with moderate or gross changes in the echostruc-
ture homogeneity. Yet, other scoring systems available
are also able to distinguish between mild and moderate
alterations in the salivary gland architecture, and even
define the number and size of the hypoechogenic areas
detected and the density of the echogenic bands within
the glands [19, 27, 30]. These scoring systems might fur-
ther ameliorate the diagnostic accuracy of SGUS for the
early detection of pSS in clinical practice. Moreover, in
our study we did not perform Doppler analysis. Actually,
contrasting data have been reported on the usefulness of
Doppler analysis for the diagnosis of pSS [11, 21]. Re-
cently, Cornec D. et al. [11] showed that Doppler wave-
form analysis and gland size measurement had poor
diagnostic performance when compared to salivary gland
inhomogeneity. In this scenario, the international at-
tempt to elaborate a novel common SGUS scoring sys-
tem will undoubtedly improve the possibility of using
SGUS for routine assessment of pSS.
Another limitation of our study in assessing the relation-
ship between SGUS findings and salivary gland dysfunction
is that we assessed the entire salivary flow rather than asses-
sing parotid and submandibular salivary fluids separately.
Therefore, we could not directly compare parotid and sub-
mandibular ultrasonography findings with the respective
alterations in major salivary gland secretory function. How-
ever, the overall concordance between parotid and
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nificant correlation between SGUS findings and salivary
flow rate abnormalities.
Conclusion
Our study represents an additional contribution to the
amount of the data supporting the use of SGUS for non-
invasive diagnosis of pSS, even in the early stages of the
disease. In the present scenario, where the international
community is striving to define more specific and sensi-
tive classification criteria for pSS, our results (once vali-
dated externally) may further evidence the usefulness
and the opportunity of including SGUS among the tests
for the diagnosis and the classification of the disease.
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